Haemonetics Operating Expenses 2010-2024 | HAE

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Haemonetics operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Haemonetics operating expenses from 2010 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$202.2B
Stryker (SYK)	$143.3B
Boston Scientific (BSX)	$130.1B
Medtronic (MDT)	$112.5B
EssilorLuxottica (ESLOY)	$111.7B
Lonza Group Ag (LZAGY)	$45.4B
Haleon (HLN)	$43.5B
GE HealthCare Technologies (GEHC)	$39.3B
ResMed (RMD)	$37B
Terumo (TRUMY)	$29.6B
Koninklijke Philips (PHG)	$25B
Zimmer Biomet Holdings (ZBH)	$21.5B
Insulet (PODD)	$18.8B
Baxter (BAX)	$17.7B
Smith & Nephew SNATS (SNN)	$10.6B
Bio-Rad Laboratories (BIO)	$10.3B
BellRing Brands (BRBR)	$9.1B
Demant (WILYY)	$8.4B
Lantheus Holdings (LNTH)	$6.1B
TG Therapeutics (TGTX)	$4.5B
ICU Medical (ICUI)	$4.3B
Prestige Consumer Healthcare (PBH)	$4B
Perrigo (PRGO)	$3.6B
Neogen (NEOG)	$3.5B
Envista Holdings (NVST)	$3.5B
Agios Pharmaceuticals (AGIO)	$3.4B
GN Store Nord (GNNDY)	$3B
Shandong Weigao Medical Polymer (SHWGF)	$3B
QuidelOrtho (QDEL)	$2.9B
LeMaitre Vascular (LMAT)	$2.3B